Michele Shimizu, MD
Family Medicine · Kamuela, HINPI 1750395273
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,958 of the $3,164 with a category attached, or 61.9%. 13 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 37.9% of the total. Reporting peaked in 2019 at $1,656 and has fallen 98.9% since, to $18 in 2024.
Across 81 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AstraZeneca$558
- Novo Nordisk$357
- Boehringer Ingelheim$281
- Daiichi Sankyo Inc.$189
- Lilly USA, LLC$173
- plus $407 from 7 others
What the payments were for
- Consulting fees$1,20038%
- Food & beverage$1,95862%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| AstraZeneca | 18 | $558 |
| Novo Nordisk | 14 | $357 |
| Boehringer Ingelheim | 13 | $281 |
| Daiichi Sankyo Inc. | 5 | $189 |
| Lilly USA, LLC | 9 | $173 |
| Pfizer | 9 | $125 |
| THD America, Inc. | 1 | $124 |
| GSK | 3 | $53 |
| Johnson & Johnson | 3 | $37 |
| Merck | 3 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- FARXIGA$226
- INJECTAFER$130
- Ozempic$119
- JARDIANCE$106
- SYMBICORT$102
How this compares
$3,164 in reported general payments places this provider in the 85th percentile of 376 family medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $108,832 |
| EliquisApixaban | 66 | $81,975 |
| MounjaroTirzepatide | 53 | $74,161 |
| JardianceEmpagliflozin | 40 | $54,344 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $42,927 |
| FarxigaDapagliflozin Propanediol | 26 | $38,480 |
| TrulicityDulaglutide | 19 | $28,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $20,088 |
| RybelsusSemaglutide | 12 | $16,788 |
| JubliaEfinaconazole | 13 | $10,528 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $9,256 |
| JanuviaSitagliptin Phosphate | 11 | $5,910 |
| Atorvastatin Calcium | 654 | $5,464 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,467 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $3,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $357 | $125,62199 claims |
| Lilly USA, LLCMounjaro, Trulicity | $173 | $102,54672 claims |
| PfizerEliquis, Premarin | $125 | $84,34378 claims |
| Boehringer IngelheimJardiance | $281 | $54,34440 claims |
| AstraZenecaFarxiga, Symbicort | $558 | $47,73756 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $53 | $24,55530 claims |
| MerckJanuvia | $35 | $5,91011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 376 family medicine providers in Hawaii.
Other family medicine in Kamuela
- Brian StolleyKihei$126K
- Vicente RamoHonolulu$34K
- Edward AlqueroWaipahu$24K
- Noelani HobbsWaipahu$23K
- Rainier Dennis BautistaLihue$23K
- Choon YeoHonolulu$20K
- Buddy FesterlingHilo$20K
- Roy KogaHilo$20K
- Stuart LernerKailua$18K
- Johanna Christa JavierKapolei$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.